{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"76.3","value":"59.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"PFS is defined as the time from first-dose to the disease progression or death from any cause. Patients who have not progressed or died are censored at the date last known progression-free.","dispersionType":"Full Range","groups":[{"description":"Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20\n\nDaratumumab: Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule","id":"OG000","title":"Daratumumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}